previous
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial
next
HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial
© 2022 MU-JHU Research Collaboration. All rights reserved